Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Hesler, Rachel A., Jennifer J. Huang, Mark D. Starr, Victoria M. Treboschi, Alyssa G. Bernanke, Andrew B. Nixon, Shannon J. McCall, Rebekah R. White, and Gerard C. Blobe. “TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.” Carcinogenesis 37, no. 11 (November 1, 2016): 1041–51. https://doi.org/10.1093/carcin/bgw093.

PMID
27604902
Full Text

Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew B. Nixon. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.” Urol Oncol 34, no. 11 (November 2016): 510–18. https://doi.org/10.1016/j.urolonc.2016.06.020.

PMID
27498927
Full Text

Hatch, Ace J., Alexander B. Sibley, Mark D. Starr, J Chris Brady, Chen Jiang, Jingquan Jia, Daniel L. Bowers, et al. “Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).” Cancer Med 5, no. 9 (September 2016): 2249–60. https://doi.org/10.1002/cam4.806.

PMID
27465221
Full Text

Keefe, S. M., J. Hoffman-Censits, R. B. Cohen, R. Mamtani, D. Heitjan, S. Eliasof, A. Nixon, et al. “Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.” Ann Oncol 27, no. 8 (August 2016): 1579–85. https://doi.org/10.1093/annonc/mdw188.

PMID
27457310
Full Text

Innocenti, Federico, Chen Jiang, Alexander Sibley, Amy Etheridge, Yoichi Furukawa, Michiaki Kubo, Hedy L. Kindler, et al. “Abstract 3388: Genetic prediction of VEGF-A plasma levels in cancer patients.” In Tumor Biology. American Association for Cancer Research, 2016. https://doi.org/10.1158/1538-7445.am2016-3388.

Full Text

Nixon, Andrew B., Alexander Sibley, Ace Joseph Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).” In Journal of Clinical Oncology, 34:3597–3597. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3597.

Full Text

Secord, Angeles Alvarez, David Tritchler, Yingmiao Liu, Mark D. Starr, John C. Brady, Heather A. Lankes, Herbert Hurwitz, et al. “Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.” In Journal of Clinical Oncology, 34:5521–5521. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5521.

Full Text

Keefe, Stephen M., Jean Hoffman-Censits, Roger B. Cohen, Scott Eliasof, Edward G. Garmey, Orvar Gunnarsson, Meliessa Hennessy, et al. “HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab.” In Bju International, 116:10–11, 2015.

Scholars@Duke

Kim, Hyung L., Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew B. Nixon, Eric J. Small, et al. “A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).” Ebiomedicine 2, no. 11 (November 2015): 1814–20. https://doi.org/10.1016/j.ebiom.2015.09.012.

PMID
26870806
Full Text

Jia, Jingquan, Andrew E. Dellinger, Eric S. Weiss, Anuradha Bulusu, Christel Rushing, Haiyan Li, Leigh A. Howard, et al. “Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.” Clin Cancer Res 21, no. 15 (August 1, 2015): 3442–52. https://doi.org/10.1158/1078-0432.CCR-14-2819.

PMID
25878330
Full Text

Pages